Laser treatment for eye floaters
Therapeutic Neodymium-doped Yttrium-Aluminum-Garnet (Nd:YAG) Laser Vitreolysis for Vitreous Floaters - A Study to Quantify Visual Quality of Life, Vitreous Structure, and Vision Before and After Nd:YAG Laser Vitreolysis in Patients With Vision Degrading Myodesopsia
NA · VMR Consulting, Inc. · NCT06915922
This study is testing if laser treatment can help people with bothersome eye floaters see better and improve their quality of life.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | VMR Consulting, Inc. (other) |
| Locations | 1 site (Huntington Beach, California) |
| Trial ID | NCT06915922 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effects of Neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser therapy on patients suffering from symptomatic vitreous floaters, which are opacities in the vitreous gel of the eye. The aim is to assess changes in quality of life, eye structure, and vision following the treatment. Only one eye per patient will be included, and participants must meet specific criteria regarding the characteristics and duration of their floaters. The FDA has approved the use of this laser for treating eye membranes, making it a viable option for addressing this condition.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with symptomatic vitreous floaters due to myopic vitreopathy or posterior vitreous detachment.
Not a fit: Patients with vitreous opacities located too close to the retina or lens, or those with significant cataracts affecting vision more than the floaters, may not benefit from this treatment.
Why it matters
Potential benefit: If successful, this treatment could significantly improve vision and quality of life for patients suffering from debilitating floaters.
How similar studies have performed: Other studies using Nd:YAG laser therapy for similar conditions have shown promising results, indicating potential effectiveness for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Only one eye per patient will be included in this study * Able and willing to give informed consent * Age ≥18 years * Suffering from symptomatic vitreous floaters * Floaters arising from either/both: * myopic vitreopathy * posterior vitreous detachment * Floaters meeting the following characteristics: * Present for ≥3 months * One single or more dense and well-defined vitreous opacities, * A Weiss Ring or opacities which are within the safety area, at least 3mm away from the retina and 6mm away from the lens * Visible on contact lens biomicroscopy Exclusion Criteria: * Patient presenting with vitreous opacities outside of the described safety area (within 3mm of the retina or 6mm from the lens) * Have clinically significant cataract (lens opacification) in one or both eyes which are in the opinion of the examining doctor more significant in impacting vision as compared to that caused by vitreous opacities; or cataract expected to need cataract surgery during the duration of the study * Present with untreated retinal tears or retinal holes requiring treatment at the discretion of the study investigator * Have high risk of peripheral lesions requiring treatment at the discretion of the study investigator * Have synchysis scintillans (unusual vitreous opacities from old blood) * Have asteroid hyalosis (unusual vitreous opacities from cholesterol) * Have vitreous hemorrhage (fresh blood in the center of the eye) * Have active photopsia (flashing lights) * History of previous YAG laser vitreolysis treatments, or vitrectomy for any condition (retinal detachment, proliferative diabetic retinopathy, etc.) * Have Posterior Vitreous Detachment (separation of vitreous away from the retina lining the inside of the back of the eye) within the past 3 months * Are unable to attend study appointments * Have any other significant ocular or non-ocular condition that, at the discretion of the study investigator, puts the subject at risk or influences the results of the study * History of intraocular surgery within 6 months from study entry * History of retinal laser within 2 months from study entry
Where this trial is running
Huntington Beach, California
- VMR Institute for Vitreous Macula Retina — Huntington Beach, California, United States (RECRUITING)
Study contacts
- Study coordinator: Dr Jerry Sebag, MD, FACS, FRCOphth, FARVO
- Email: JSebag@vmrinstitute.com
- Phone: 714-901-7777
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Posterior Vitreous Detachment, Myopic Vitreopathy, VISION DEGRADING MYODESOPSIA